- Home
- CDNA vs PRME Comparison
CDNA vs PRME Comparison
Compare CDNA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDNA | PRME |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.2M | 601.1M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CDNA | PRME |
|---|---|---|
| Price | $20.58 | $4.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $26.00 | $9.31 |
| AVG Volume (30 Days) | 816.3K | ★ 3.8M |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $357,998,000.00 | $5,977,000.00 |
| Revenue This Year | $14.11 | $111.80 |
| Revenue Next Year | $12.00 | N/A |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | 14.46 | ★ 647.13 |
| 52 Week Low | $10.96 | $1.11 |
| 52 Week High | $25.95 | $6.94 |
Technical Indicators
Market Signals| Indicator | CDNA | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 71.98 | 52.01 |
| Support Level | $18.36 | $3.95 |
| Resistance Level | $19.95 | $4.42 |
| Average True Range (ATR) | 0.86 | 0.30 |
| MACD | 0.19 | 0.12 |
| Stochastic Oscillator | 99.42 | 76.72 |
Price Performance
Historical ComparisonAbout CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.